Navigation Links
AMT: Glybera(R) Lowers Pancreatitis Incidence Significantly

AMSTERDAM, The Netherlands, January 28 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today during the Phacilitate Cell & Gene Therapy Forum new data showing that one treatment of its lead product Glybera(R) results in a long term significant and clinically important lowering of the incidence of acute pancreatitis in Lipoprotein Lipase Deficient patients. Recurrent acute pancreatitis is the most debilitating complication of Lipoprotein Lipase Deficiency (LPLD) and is associated with significant morbidity and mortality.

To date only one patient from the two clinical trials had an acute pancreatitis during the long-term follow-up, while seven episodes of pancreatitis would have been expected based on the observational studies in the same patients. This equals a lowering of the incidence of pancreatitis from 0.33 per patient per year to 0.05 for both trials. The data were obtained from two observational and two interventional clinical studies with 22 patients and follow up data from 1 to 3.5 years after the treatment. The studies result in a total of more than 38 patient years worth of data.

Other positive effects of Glybera are the disappearance or reduction of fat accumulations in the skin or retina. The data also confirm that the treatment is well-tolerated and safe.

AMT has developed Glybera as an effective treatment for patients with the rare genetic disorder LPLD. Because of a defective gene, LPLD patients do not produce an enzyme that normally breaks down a certain type of fat carrying particles in the blood. Glybera is a gene therapy, which restores the enzyme (lipoprotein lipase) activity required to process the fat carrying particles. LPLD patients have extremely high fat levels in their blood, resulting in recurrent and potentially lethal pancreatitis as well as an increased risk of cardiovascular complications and diabetes. Currently, there exists no effective treatment or cure for this serious disease.

About Amsterdam Molecular Therapeutics

AMT has a unique gene therapy platform that to date appears to circumvent many if not all of the obstacles that have prevented gene therapy from becoming a mainstay of clinical medicine. Using adeno-associated viral (AAV) vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate what is probably the first stable and scalable AAV production platform. As such, AMT's proprietary platform holds tremendous promise for thousands of rare (orphan) diseases that are caused by one faulty gene. AMT currently has a product pipeline with seven products at different stages of development.

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of Amsterdam Molecular Therapeutics only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT's business, including, but not limited to, the timely commencement and success of AMT's clinical trials and research endeavors, delays in receiving U.S. Food and Drug Administration or other regulatory approvals (i.e. EMEA, Health Canada), market acceptance of AMT's products, effectiveness of AMT's marketing and sales efforts, development of competing therapies and/or technologies, the terms of any future strategic alliances, the need for additional capital, the inability to obtain, or meet, conditions imposed for required governmental and regulatory approvals and consents. AMT expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. For a more detailed description of the risk factors and uncertainties affecting AMT, refer to the prospectus of AMT's initial public offering on June 20, 2007, and AMT's public announcements made from time to time.

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. AMT Prepares for Submission of Marketing Authorization Dossier for AMT-011 (Glybera(R))
2. AMT Intends to Incorporate Additional Data to its Marketing Authorization Dossier for Glybera(R)
3. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
4. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
5. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
6. Kmart Lowers Flu Shot Price to $10
7. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
8. BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients
9. New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients
10. Dronedarone (Multaq(R)) Reduced the Incidence and Duration of Hospitalization in Patients with Atrial Fibrillation
11. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
Post Your Comments:
(Date:12/1/2015)... -- A large study of patients with breast cancer who ... found no increased risk of recurrence. The Kaiser Permanente ... National Cancer Institute. --> ... drug taken by women with breast cancer to reduce ... for five years, but has notable side effects, including ...
(Date:12/1/2015)... BOTHELL Wash. and VANCOUVER ... Monitoring Committee (DMC) meeting, OncoGenex Pharmaceuticals, Inc. (NASDAQ: ... trial is continuing based on the pre-planned interim futility ... safety review, no new safety issues were identified by ... to all analyses and final results are expected in ...
(Date:12/1/2015)... HERNDON, Va. , Dec. 1, 2015 ... (FDA) Drug Supply Chain Security Act (DSCSA) approaches, ... helping small and independent pharmacies comply with looming ... --> InfiniTrak is entering endorsement agreements with ... a pharmacy services administration organization (PSAO) to exclusively ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... The Multiple System Atrophy Coalition has announced ... Multiple System Atrophy (MSA) research, timed today to coincide with Giving Tuesday 2015, a ... including their ability to work and be productive, to do simple daily activities like ...
(Date:12/1/2015)... ... December 02, 2015 , ... ClinicoEconomics and Outcomes Research ... of treatment for osteoporosis ”. , As corresponding author Dr Ankita Modi says ... with osteoporosis. Based on a large US managed care database, women aged 55 ...
(Date:12/1/2015)... ... December 01, 2015 , ... According to an ... has filed a discrimination claim against the U.S. Department of Health and Human Services, ... Care Act (ACA) plans are breaking the clause in the law prohibiting the denial ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Paul Vitenas, one of the ... named by MedEsthetics magazine as the Best Single Physician Practice in the nation. Dr. ... elite aesthetic physicians honored by the industry publication. , Dr. Vitenas said he ...
(Date:12/1/2015)... York, NY (PRWEB) , ... December 01, 2015 ... ... epidemic in the 1980s we have seen vast improvements in scientific research and ... made significant strides, providing increased hope and relief to those affected by HIV/AIDS. ...
Breaking Medicine News(10 mins):